Futaibi (COVID-19 Vaccine) Co., Ltd. (BNT 162b2)? This is an mRNA (Messenger RNA) COVID-19 vaccine. MRNA is a naturally occurring molecule with the blueprint of human cells, which can produce target proteins or immunogens, activate immune responses in vivo and fight against various pathogens.
The mRNA vaccine uses the gene sequence of the virus, not the virus itself. Therefore, the mRNA vaccine has no virus component and there is no risk of infection. At the same time, the research and development cycle of mRNA vaccine is short, and new candidate vaccines can be developed quickly to deal with virus variation. The dual mechanism of humoral immunity and T cell immunity has strong immunogenicity, does not need adjuvant, and is easy to produce on a large scale, which supports the key advantages of global supply.
All vaccines, including mRNA and traditional vaccines, prevent virus infection by activating the immune system, and produce persistent antibodies and T cell responses against novel coronavirus.
Extended data
COVID-19 vaccine (BNT16B2, Chinese trade name: Fubitai TM) based on Biotech mRNA technology by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and BioNTech SE has been approved for emergency use by the Food and Health Bureau of Hong Kong Special Administrative Region.
On the morning of April 5th, 200212002, Hong Kong people lined up in front of the sun yat sen memorial park Gymnasium Community Vaccination Center, ready to receive the vaccine of Fubitai.
On March 24th, 20021year, due to the defects in the packaging of Fubitai vaccine, vaccination was suspended. After a lapse of 12 days, the vaccination of Fubitai resumed.
References:
Beiqing. Com- Hong Kong resumed the vaccination of Fubitai, and citizens lined up for vaccination.